Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This prospective, randomized, double-blind controlled trial aims to evaluate whether intravenous papaverine, administered immediately after the removal of a double-balloon catheter used for cervical ripening, can shorten the duration of labor in term pregnant women undergoing induction of labor. Papaverine is an antispasmodic medication that relaxes smooth muscle and is commonly used in obstetrics, although its effect on labor progression following mechanical cervical ripening has not been fully studied.
Eligible participants include nulliparous and multiparous women with a singleton pregnancy at 37-42 weeks, admitted for induction of labor with a double-balloon catheter. After catheter removal, participants will be randomized in a 1:1 ratio to receive either 80 mg intravenous papaverine or placebo (normal saline), administered by the midwife who is not involved in clinical decision-making. Clinical staff and participants will remain blinded to group allocation.
The primary outcomes are the time from drug administration to complete cervical dilation and the duration of the second stage of labor. Secondary outcomes include mode of delivery, maternal complications (such as perineal tears and postpartum hemorrhage), oxytocin augmentation duration and maximum dose, and neonatal outcomes.
This study seeks to determine whether papaverine can safely and effectively reduce labor duration following mechanical cervical ripening.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Arm Name: Papaverine | Experimental | "Participants receive 80 mg intravenous papaverine immediately after removal of the double-balloon catheter, together with initiation of oxytocin augmentation." |
|
| Arm Type: Placebo Comparator | Placebo Comparator | "Participants receive intravenous normal saline immediately after removal of the double-balloon catheter, together with initiation of oxytocin augmentation." |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Papaverine 80 mg IV | Drug | Single intravenous dose of 80 mg papaverine administered immediately after removal of the double-balloon cervical ripening catheter. The medication is given by the midwife as part of the randomized, double-blind protocol, followed by initiation of oxytocin augmentation according to standard labor management. |
| Measure | Description | Time Frame |
|---|---|---|
| Time from study drug administration to complete cervical dilation | Time in hours from intravenous administration of papaverine or placebo after removal of the double-balloon catheter until complete cervical dilation (10 cm), as documented in the partogram/electronic medical record. | From study drug administration to complete cervical dilation, up to 24 hours. |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
"Only pregnant individuals who identify as female are eligible to participate. The study population consists exclusively of pregnant women admitted for induction of labor at term."
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Esther Maor-Sagie, MD | Contact | 9727744248 | estimaorsagie@gmail.com | |
| Rinat Gabbay-Benziv, Prof | Contact | +972-4-7744514 | rinatg@hymc.gov.il |
| Name | Affiliation | Role |
|---|---|---|
| Esther Maor-Sagie, MD | Hillel Yaffe Medical Center | Principal Investigator |
| Rinat Gabbay-Benziv, Prof | Hillel Yaffe Medical Center | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hillel Yaffe Medical Center | Recruiting | Hadera | Israel |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010208 | Papaverine |
| D000077330 | Saline Solution |
| ID | Term |
|---|---|
| D044182 | Benzylisoquinolines |
| D000470 | Alkaloids |
| D006571 | Heterocyclic Compounds |
| D053610 | Opiate Alkaloids |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Placebo (Normal Saline) | Drug | Single intravenous dose of normal saline administered immediately after removal of the double-balloon cervical ripening catheter. The placebo is administered in an identical manner to the papaverine intervention as part of the randomized, double-blind protocol, followed by initiation of oxytocin augmentation. |
|
| D007546 |
| Isoquinolines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D000077324 | Crystalloid Solutions |
| D007552 | Isotonic Solutions |
| D012996 | Solutions |
| D004364 | Pharmaceutical Preparations |